Gonadorelin vs Liothyronine (T3)
A side-by-side research comparison of Gonadorelin and Liothyronine (T3) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Gonadorelin | Liothyronine (T3) |
|---|---|---|
| Full name | Gonadorelin (GnRH Analog) | Liothyronine Sodium (Cytomel) |
| Category | Hormone Replacement | Hormone Replacement |
| Status | FDA Approved | Prescription medication |
| Mechanism | Binds GnRH receptors on pituitary gonadotrophs to stimulate LH and FSH release, maintaining testicular/ovarian function and natural sex hormone production. | Binds nuclear thyroid receptors to regulate gene transcription for basal metabolic rate, thermogenesis, protein synthesis, and carbohydrate/fat metabolism in virtually every tissue. |
| Molecular weight | 1182.39 Da | 650.97 Da |
| Half-life | ~10-40 minutes | ~2.5 days |
| Bioavailability | ~90% subcutaneous | ~95% oral |
| Typical dose | 100-500 mcg | 5-25 mcg |
| Frequency | 2-3x per week or pulsatile | Daily (split AM/PM) |
| Route | Subcutaneous injection | Oral tablet or sustained-release capsule |
Gonadorelin reported benefits
- Maintains natural hormone production
- Fertility preservation
- Testicular function support
- LH/FSH normalization
Liothyronine (T3) reported benefits
- Metabolic rate increase
- Weight loss support
- Improved energy
- Better mood
- Reduced brain fog
- Enhanced fat oxidation
Related comparisons
Research and educational reference only. Not medical advice.